ATE500326T1 - Gene und proteine mit bezug zu menschlichem kolonkrebs - Google Patents
Gene und proteine mit bezug zu menschlichem kolonkrebsInfo
- Publication number
- ATE500326T1 ATE500326T1 AT03730791T AT03730791T ATE500326T1 AT E500326 T1 ATE500326 T1 AT E500326T1 AT 03730791 T AT03730791 T AT 03730791T AT 03730791 T AT03730791 T AT 03730791T AT E500326 T1 ATE500326 T1 AT E500326T1
- Authority
- AT
- Austria
- Prior art keywords
- genes
- colon cancer
- human colon
- proteins related
- whose expression
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000029742 colonic neoplasm Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 abstract 1
- 101100232787 Homo sapiens IGSF11 gene Proteins 0.000 abstract 1
- 102100021032 Immunoglobulin superfamily member 11 Human genes 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38698502P | 2002-06-06 | 2002-06-06 | |
| US41520902P | 2002-09-30 | 2002-09-30 | |
| US45101303P | 2003-02-28 | 2003-02-28 | |
| PCT/JP2003/007006 WO2003104275A2 (en) | 2002-06-06 | 2003-06-03 | Genes and polypeptides relating to human colon cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500326T1 true ATE500326T1 (de) | 2011-03-15 |
Family
ID=29740821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03730791T ATE500326T1 (de) | 2002-06-06 | 2003-06-03 | Gene und proteine mit bezug zu menschlichem kolonkrebs |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7425612B2 (de) |
| EP (3) | EP2233572A3 (de) |
| JP (3) | JP4594085B2 (de) |
| KR (2) | KR101031025B1 (de) |
| CN (1) | CN100532549C (de) |
| AT (1) | ATE500326T1 (de) |
| AU (2) | AU2003241179C1 (de) |
| BR (1) | BRPI0311822B8 (de) |
| CA (1) | CA2488404C (de) |
| CY (1) | CY1112052T1 (de) |
| DE (1) | DE60336227D1 (de) |
| DK (1) | DK1513934T3 (de) |
| HK (1) | HK1083521A1 (de) |
| MX (1) | MXPA04012225A (de) |
| PT (1) | PT1513934E (de) |
| SG (1) | SG145559A1 (de) |
| WO (1) | WO2003104275A2 (de) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101613405A (zh) * | 2002-06-06 | 2009-12-30 | 肿瘤疗法科学股份有限公司 | 与人结肠癌相关的基因和多肽 |
| SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
| EP2286844A3 (de) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antikörper-Arzneimittelkonjugate und Verfahren |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| WO2006110585A2 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes (prlr) |
| ES2397441T5 (es) | 2006-02-13 | 2022-09-14 | Daiichi Sankyo Co Ltd | Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| KR100877554B1 (ko) * | 2006-03-30 | 2009-01-07 | 재단법인 한국원자력의학원 | 간암 환자 생존기간 예측용 마커, 그를 포함하는 키트 및마이크로어레이, 및 상기 마커를 이용한 간암 환자생존기간 예측 방법 |
| DK2918598T3 (en) * | 2007-02-28 | 2019-04-29 | The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services | Brachyury polypeptides and methods of use |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| WO2010106770A1 (en) | 2009-03-18 | 2010-09-23 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
| EP2448966B1 (de) | 2009-07-03 | 2018-11-14 | Avipep Pty Ltd | Immunkonjugate und verfahren zu ihrer herstellung |
| AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
| AU2010336029B2 (en) | 2009-12-23 | 2011-10-13 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them 2 |
| PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
| EP2579897A1 (de) | 2010-06-08 | 2013-04-17 | Genentech, Inc. | Cystein-manipulierte antikörper und konjugate |
| ES2544608T3 (es) | 2010-11-17 | 2015-09-02 | Genentech, Inc. | Conjugados de anticuerpo y de alaninil-maitansinol |
| WO2012073459A1 (en) | 2010-12-02 | 2012-06-07 | Oncotherapy Science, Inc. | Tomm34 peptides and vaccines including the same |
| AU2012245073B2 (en) | 2011-04-21 | 2016-02-11 | Garvan Institute Of Medical Research | Modified variable domain molecules and methods for producing and using them b |
| CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
| HUE025661T2 (en) | 2011-10-14 | 2016-04-28 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
| US9296826B2 (en) | 2011-10-14 | 2016-03-29 | Novartis Ag | Antibodies and methods for WNT pathway-related diseases |
| ES2797533T3 (es) * | 2012-02-28 | 2020-12-02 | Novartis Ag | Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43 |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
| JP6268173B2 (ja) | 2012-07-19 | 2018-01-24 | 第一三共株式会社 | 抗Ｓｉｇｌｅｃ−１５抗体 |
| EP2906297B1 (de) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepin-antikörper-konjugate |
| NZ707534A (en) | 2012-10-12 | 2018-08-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| NZ707486A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| DK2906251T3 (da) | 2012-10-12 | 2017-11-20 | Adc Therapeutics Sa | Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| MX364328B (es) | 2012-10-12 | 2019-04-23 | Medimmune Ltd | Conjugados del anticuerpo pirrolobenzodiazepina. |
| PL2766048T3 (pl) | 2012-10-12 | 2015-05-29 | Medimmune Ltd | Pirolobenzodiazepiny i ich koniugaty |
| CN110452242A (zh) | 2012-12-21 | 2019-11-15 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CA2894959C (en) | 2012-12-21 | 2022-01-11 | Spirogen Sarl | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| CN105142674B (zh) | 2013-03-13 | 2018-11-13 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓和其结合物 |
| US20160031887A1 (en) | 2013-03-13 | 2016-02-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014244245C1 (en) | 2013-03-13 | 2018-04-19 | Genentech, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| CN103320445B (zh) * | 2013-07-11 | 2017-07-28 | 重庆市肿瘤研究所 | 特异性识别胃癌细胞的dna适配子gca‑5及其应用 |
| EA201690195A1 (ru) | 2013-08-12 | 2016-05-31 | Дженентек, Инк. | Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054986B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3082875B1 (de) | 2013-12-16 | 2020-11-25 | Genentech, Inc. | Peptidomimetische verbindungen und antikörper-wirkstoff-konjugate davon |
| MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
| CN105873614B (zh) | 2013-12-16 | 2020-10-30 | 基因泰克公司 | 肽模拟化合物及其抗体-药物缀合物 |
| EP3193940A1 (de) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate daraus |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| AR101844A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos y conjugados modificados genéticamente con cisteína |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| JP2017533887A (ja) | 2014-09-17 | 2017-11-16 | ジェネンテック， インコーポレイテッド | ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート |
| KR20170101895A (ko) | 2014-11-25 | 2017-09-06 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 접합체 |
| KR20170086121A (ko) | 2014-12-03 | 2017-07-25 | 제넨테크, 인크. | 4급 아민 화합물 및 그의 항체-약물 접합체 |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| JP6943872B2 (ja) | 2016-03-25 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 多重全抗体及び抗体複合体化薬物定量化アッセイ |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック， インコーポレイテッド | 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法 |
| US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| EP3494141A4 (de) | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | Identifizierung von vsig3/vista als ein neuartiger immuncheckpoint und verwendung davon zur immuntherapie |
| EP3496763A1 (de) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon |
| WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| NZ753307A (en) | 2016-11-30 | 2023-10-27 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| AU2018217926B2 (en) | 2017-02-08 | 2019-10-03 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3612537B1 (de) | 2017-04-18 | 2022-07-13 | Medimmune Limited | Pyrrolobenzodiazepinkonjugate |
| US20200129637A1 (en) | 2017-04-20 | 2020-04-30 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| KR102442736B1 (ko) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| JP7220203B2 (ja) | 2017-08-18 | 2023-02-09 | メドイミューン・リミテッド | ピロロベンゾジアゼピン複合体 |
| IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thylanstatin analogs |
| KR20200070405A (ko) * | 2017-11-08 | 2020-06-17 | 어드박시스, 인크. | 암 관련 단백질로부터의 면역원성 불규칙변화성 펩타이드 및 그것의 사용 방법 |
| EP3508499A1 (de) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antikörper zum targeting von, und andere modulatoren von, einem immunglobulingen im zusammenhang mit resistenz gegen antitumor-immunantworten und verwendungen davon |
| US11787857B2 (en) | 2018-02-02 | 2023-10-17 | Bio-Techne Corporation | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| EP3870235A1 (de) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Konjugierte chemische abbauauslöser und verwendungsverfahren |
| CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| WO2021005009A1 (en) | 2019-07-05 | 2021-01-14 | Iomx Therapeutics Ag | Antibodies binding igc2 of igsf11 (vsig3) and uses thereof |
| EP4175668A1 (de) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Igv von igsf11 (vsig3) bindende antikörper und verwendungen davon |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0239102A3 (de) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Verfahren zur Herstellung eines Human-Human-Hybridoms |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1993002227A1 (en) | 1991-07-15 | 1993-02-04 | Eco-Tec Limited | Process and apparatus for treating fluoride containing acid solutions |
| JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス，インク． | 異種抗体の生産 |
| EP0754225A4 (de) | 1993-04-26 | 2001-01-31 | Genpharm Int | Heterologe antikörper produzierende transgene nicht-humane tiere |
| KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO2000050588A2 (en) * | 1999-02-22 | 2000-08-31 | Incyte Pharmaceuticals, Inc. | Genes associated with diseases of the colon |
| CA2384713A1 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| WO2001055387A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001054472A2 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001060860A2 (en) * | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
| WO2001066689A2 (en) * | 2000-03-07 | 2001-09-13 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20030228584A1 (en) * | 2000-03-07 | 2003-12-11 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| WO2002026930A2 (en) * | 2000-09-26 | 2002-04-04 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20030064411A1 (en) * | 2000-12-08 | 2003-04-03 | Herath Herath Mudiyanselage Athula Chandrasiri | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease |
| EP1537138A2 (de) * | 2001-07-17 | 2005-06-08 | Incyte Genomics, Inc. | Rezeptoren und membranassoziierte proteine |
| JP2003245084A (ja) * | 2001-12-20 | 2003-09-02 | Morinaga Milk Ind Co Ltd | 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途 |
-
2003
- 2003-06-03 CN CNB038189437A patent/CN100532549C/zh not_active Expired - Lifetime
- 2003-06-03 WO PCT/JP2003/007006 patent/WO2003104275A2/en active Application Filing
- 2003-06-03 EP EP10164543A patent/EP2233572A3/de not_active Withdrawn
- 2003-06-03 CA CA2488404A patent/CA2488404C/en not_active Expired - Lifetime
- 2003-06-03 JP JP2004511343A patent/JP4594085B2/ja not_active Expired - Lifetime
- 2003-06-03 PT PT03730791T patent/PT1513934E/pt unknown
- 2003-06-03 KR KR1020047019876A patent/KR101031025B1/ko active IP Right Review Request
- 2003-06-03 AT AT03730791T patent/ATE500326T1/de active
- 2003-06-03 BR BRPI0311822A patent/BRPI0311822B8/pt not_active IP Right Cessation
- 2003-06-03 DK DK03730791.5T patent/DK1513934T3/da active
- 2003-06-03 EP EP03730791A patent/EP1513934B1/de not_active Expired - Lifetime
- 2003-06-03 AU AU2003241179A patent/AU2003241179C1/en not_active Expired
- 2003-06-03 EP EP10177795A patent/EP2275544A3/de not_active Withdrawn
- 2003-06-03 KR KR1020107022697A patent/KR101077177B1/ko not_active IP Right Cessation
- 2003-06-03 MX MXPA04012225A patent/MXPA04012225A/es active IP Right Grant
- 2003-06-03 DE DE60336227T patent/DE60336227D1/de not_active Expired - Lifetime
- 2003-06-03 SG SG200601081-3A patent/SG145559A1/en unknown
-
2004
- 2004-08-10 US US10/916,064 patent/US7425612B2/en not_active Expired - Lifetime
-
2006
- 2006-03-21 HK HK06103520.7A patent/HK1083521A1/xx not_active IP Right Cessation
-
2008
- 2008-07-17 US US12/175,092 patent/US7847065B2/en not_active Expired - Fee Related
- 2008-07-25 US US12/180,204 patent/US7705141B2/en not_active Expired - Lifetime
-
2009
- 2009-03-27 JP JP2009078559A patent/JP5069268B2/ja not_active Expired - Fee Related
- 2009-12-03 AU AU2009243506A patent/AU2009243506A1/en not_active Abandoned
-
2010
- 2010-10-22 US US12/910,015 patent/US20120190628A1/en not_active Abandoned
-
2011
- 2011-05-18 CY CY20111100487T patent/CY1112052T1/el unknown
- 2011-08-18 JP JP2011178673A patent/JP2012019791A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE500326T1 (de) | Gene und proteine mit bezug zu menschlichem kolonkrebs | |
| WO2004031411A3 (en) | Genes and polypeptides relating to human pancreatic cancers | |
| WO2003104276A3 (en) | GENES AND POLYPEPTIDES RELATED TO HEPATOCELLULAR OR COLORECTAL CARCINOMA | |
| CY1121975T1 (el) | Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους | |
| Yim et al. | Optimization of a protease activated probe for optical surgical navigation | |
| Nigim et al. | Emerging medical treatments for meningioma in the molecular era | |
| BR0315666A (pt) | Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos | |
| ATE454159T1 (de) | Von survivin abgeleitete peptide und deren verwendung | |
| NO20051423L (no) | RNAi-prober som malsoker cancer-relaterte proteiner | |
| DE60019273D1 (de) | Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung | |
| WO2004031231A3 (en) | Genes and polypeptides relating to prostate cancers | |
| WO2006061216A3 (en) | Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment | |
| HK1093674A1 (en) | Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer | |
| WO2004092338A3 (en) | Compositions, splice variants and methods relating to cancer specific genes and proteins | |
| AR026946A1 (es) | Osteoprotegerina/receptores de factores de necrosis de tumores | |
| DE602005025231D1 (de) | Gene und polypeptide in verbindung mit brustkrebserkrankungen | |
| WO2002031209A3 (en) | Genes related to development of refractory prostate cancer | |
| Berman et al. | Investigative pathology: Leading the post-genomic revolution | |
| TW200502247A (en) | Genes and polypeptides relating to human colon cancers | |
| Tiffin et al. | Sex hormone receptor immunohistochemistry staining in Barrett's oesophagus and adenocarcinoma. | |
| WO2007013479A3 (en) | Genes and polypeptides relating to prostate cancers | |
| WO2001081341A3 (de) | 9-oxa-epothilon-derivate, verfahren zu deren herstellung sowie ihre verwendung in pharmazeutischen präparaten | |
| Camara | Do the gut and skin microbiomes share thoughts on melanoma development? | |
| Santos et al. | Gastrointestinal metastatic melanoma: the key for diagnosis | |
| Bapat | Cancer stem cells: identification and targets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1513934 Country of ref document: EP |